Several types of leukemia are curable, particularly when diagnosed early or in younger patients. Childhood acute lymphoblastic leukemia (ALL) has the highest cure rates, with about 85% of children achieving long-term, disease-free survival. Adult leukemias are harder to cure, but meaningful percentages of patients with acute forms do achieve lasting remission, and chronic myelogenous leukemia (CML) can now be controlled so effectively that some patients stop treatment entirely and remain cancer-free.
The four major types of leukemia each carry different odds, and “cure” in leukemia has a specific meaning: staying in complete remission long enough that the cancer is unlikely to return. For most acute leukemias, that threshold is roughly five years, after which the relapse rate drops to less than 3%.
Childhood ALL: The Most Curable Leukemia
Acute lymphoblastic leukemia in children is the clearest success story in cancer medicine. About 98% of children with ALL achieve remission after initial treatment, and more than 90% are alive at five years. Roughly 85% of patients aged 1 to 18 are expected to be long-term event-free survivors, meaning they stay in remission without relapse or significant complications. These numbers have improved dramatically over the past several decades, up from a 60% five-year survival rate in earlier eras.
Teenagers and young adults (ages 15 to 19) don’t do quite as well, but their outcomes have also improved sharply, from 28% five-year survival historically to more than 75% today. The younger the patient, the better the odds tend to be.
Adult ALL: Lower but Real Cure Rates
Adults with ALL face tougher odds than children, partly because adult leukemia cells more often carry genetic changes that make them resistant to treatment. Still, a significant portion of adults achieve durable remission. Stem cell transplants from a donor are one of the most effective paths to cure for adults with ALL. One study found a 10-year survival rate of 81% for ALL patients who underwent this type of transplant.
For adults whose ALL comes back after standard treatment or doesn’t respond to it, a newer approach called CAR-T cell therapy has shown remarkable results. This treatment reprograms a patient’s own immune cells to attack leukemia. In clinical trials of children and young adults with relapsed ALL, 90% or more achieved complete remission after infusion. About 50% to 60% remained relapse-free at one year, which is striking for a group that previously had very few options. These results continue to improve as the therapy is refined.
Acute Myeloid Leukemia (AML): Cure Depends on Age
AML is the most common acute leukemia in adults, and its curability varies significantly by age. Overall, about 32% of AML patients are alive five years after diagnosis. More than 25% of adults with AML can be expected to survive three or more years and may be cured, which represents roughly 45% of those who achieve complete remission in the first place.
Age is the single biggest factor. Patients younger than 60 have remission rates above 65%, and their chances of long-term cure are substantially higher than older patients. The genetic profile of the leukemia also matters enormously. Certain mutations create a more favorable outlook, while others, particularly those involving the TP53 gene or complex chromosomal changes, predict much worse outcomes. Two patients with AML can have very different prognoses based entirely on which mutations their cancer carries.
Stem cell transplant from a donor remains one of the strongest tools for curing AML, with one study reporting a 76% ten-year survival rate among transplant recipients. Most AML relapses happen within three years of diagnosis. Late relapse, occurring after five years of remission, is rare, affecting fewer than 3% of patients. Once you pass that five-year mark, the cancer is very unlikely to come back.
Chronic Myelogenous Leukemia (CML): A Functional Cure
CML was once a fatal diagnosis, but targeted drugs called tyrosine kinase inhibitors transformed it into a manageable condition. Patients taking these daily pills can now expect a nearly normal lifespan. The first of these drugs, imatinib, arrived in the early 2000s and fundamentally changed the disease.
Whether CML is “cured” depends on your definition. Most patients take medication indefinitely to keep the disease suppressed. But a growing subset can actually stop treatment and stay in remission. In a U.S. clinical study, about 66% of patients who stopped their medication remained in remission three years later, and most were still in remission at the four-year mark. These were patients who had been in deep remission for at least three years before stopping.
The catch is that only about 20% to 25% of all CML patients meet the criteria to safely try stopping treatment. Those who do must be closely monitored with regular blood tests, because if the disease returns, they need to restart medication promptly. Researchers consider complete, permanent freedom from both the disease and treatment to be the ultimate goal, and that remains achievable for a meaningful minority of patients.
Chronic Lymphocytic Leukemia (CLL): Manageable but Not Curable
CLL is the one major leukemia type that is generally not considered curable with current treatments. It tends to be slow-growing, and many patients live for years, sometimes decades, without needing treatment at all. Among patients who remain untreated at year 10 after diagnosis, the relative survival rate is about 89%, meaning their life expectancy is close to that of someone without the disease.
The lack of a curative treatment doesn’t necessarily mean a shortened life. Many people diagnosed with CLL, especially those with early-stage or slow-progressing disease, are monitored without any therapy in a “watch and wait” approach. When treatment is needed, modern drugs can control the disease effectively for long periods. The five-year relative survival at diagnosis is about 73%, which improves the longer a patient goes without needing treatment. Still, because CLL tends to recur after therapy, it is classified as a chronic condition rather than a curable one.
What Determines Whether Your Leukemia Is Curable
Beyond the type of leukemia, several factors shape whether a cure is realistic. Age is the most influential: younger patients consistently have better outcomes across every leukemia type. The genetic mutations driving the cancer matter nearly as much. In AML, for instance, certain mutation patterns in a gene called NPM1 predict favorable outcomes, while TP53 mutations signal a much harder road.
How quickly and deeply the cancer responds to initial treatment is another strong predictor. Doctors now measure remission at a molecular level, looking for traces of leukemia too small to see under a microscope. Patients who reach this deep level of remission, sometimes called “measurable residual disease negative,” have significantly better long-term outcomes than those who achieve only a standard remission.
Stem cell transplant from a matched donor remains the most powerful curative tool for aggressive leukemias that are unlikely to be cured by chemotherapy alone. It carries serious risks, including graft-versus-host disease and infection, but for high-risk patients it offers the best chance at a permanent cure. Newer options like CAR-T cell therapy are expanding the possibilities for patients whose leukemia resists conventional treatment, turning some previously incurable situations into ones where long-term remission is possible.